L2 was founded in 1998 as a provider of novel diagnostic services for systemic lupus erythematosus and Lyme disease. The company rapidly evolved a new emphasis on developing novel diagnostic tools in a number of areas, discovering new vaccines and the development of small molecule therapeutics. Our current research activity is summarized on the Research page on this site.
Many of our projects are supported by the National Institutes for Health, Department of Defense, and private foundations.
L2's collegial approach to science leverages the efforts of our scientists through multi-disciplinary collaborations with over 30 universities and pharmaceutical service companies world-wide.
This network of collaborative laboratories, together with several independent consultants, affords L2 access to an extraordinary wealth of knowledge, expertise, and equipment to foster multi-disciplinary research between the private and public sectors.
The NIH requires that all "Recipient Institutions" maintain an up-to-date, written, enforced policy on financial conflicts of interest that complies with the NIH regulations. The L2 policy is available here.